Technical Analysis for VTGN - VistaGen Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.7253 5.22% 0.04
VTGN closed up 5.22 percent on Friday, January 17, 2020, on 40 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical VTGN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Bollinger Band Squeeze Range Contraction 5.22%
Narrow Range Bar Range Contraction 5.22%
BB Squeeze Started Range Contraction 5.22%
Crossed Above 50 DMA Bullish 5.96%
Narrow Range Bar Range Contraction 5.96%
NR7 Range Contraction 5.96%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary new chemical entities (NCEs) for internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and liver cells derived from hPSC technology. The company is also involved in the development of CardioSafe 3D, an in vitro bioassay system for predicting potential cardiotoxicity of new chemical entities (NCEs), including drug rescue NCEs; and LiverSafe 3D, a bioassay system to predict potential liver toxicity of new drug candidates, including potential drug metabolism issues and adverse drug-drug interactions. It has strategic collaborations with University Health Network for hPSC technology research and development; Synterys, Inc. to design, produce, and analyze drug rescue NCEs; and Cato Research, Ltd. for regulatory expertise and clinical development support. The company also has cooperative research and development agreement with the U.S. National Institute of Mental Health for the Phase II clinical study of AV-101. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Health Biopharmaceutical Pharmaceutical Industry Diseases Drug Discovery Clinical Trial Disorders Health Sciences Regenerative Medicine Pharmaceutical Sciences Major Depressive Disorder Antidepressants Treatment Of Major Depressive Disorder Clinical Pharmacology Nmda Receptor Antagonists Chemical Entities Drug Metabolism

Is VTGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.86
52 Week Low 0.2943
Average Volume 960,030
200-Day Moving Average 0.81
50-Day Moving Average 0.65
20-Day Moving Average 0.71
10-Day Moving Average 0.69
Average True Range 0.08
ADX 22.6
+DI 28.31
-DI 20.35
Chandelier Exit (Long, 3 ATRs ) 0.79
Chandelier Exit (Short, 3 ATRs ) 0.87
Upper Bollinger Band 0.80
Lower Bollinger Band 0.63
Percent B (%b) 0.57
BandWidth 23.62
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.0022
Fundamentals Value
Market Cap 6.8 Million
Num Shares 9.38 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 7.65
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.83
Resistance 3 (R3) 0.82 0.79 0.81
Resistance 2 (R2) 0.79 0.76 0.79 0.80
Resistance 1 (R1) 0.76 0.74 0.77 0.76 0.80
Pivot Point 0.72 0.72 0.73 0.72 0.72
Support 1 (S1) 0.69 0.69 0.70 0.69 0.65
Support 2 (S2) 0.65 0.68 0.65 0.65
Support 3 (S3) 0.62 0.65 0.64
Support 4 (S4) 0.62